Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitized scalp-cooling system used in 74 patients
Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: A pilot study of a new digitized scalp-cooling system used in 74 patients
复制标题
DOI：
10.1007/s00520-003-0451-y
复制
发表时间：
2003-06-01
影响因子：
3.1
通讯作者：
Gustavsson, A
中科院分区：
文献类型：
--
作者：
Ridderheim, M;Bjurberg, M;Gustavsson, A
目标：本研究的目的是检查新型数字化、受控、头皮冷却系统预防化疗引起的脱发的有效性和安全性。方法：一项非随机试验研究纳入了 74 名接受 13 种不同化疗方案的女性癌症患者。配备 Dignicap 系统的 Digni 2-3 由冰箱单元和控制单元组成，集成到移动柜中并连接到紧密配合的冷却盖。该系统可将头皮温度保持在+5°C 数小时。在这项研究中，60 名卵巢癌患者接受了紫杉烷或表柔比星联合化疗。还包括八名霍奇金淋巴瘤患者、三名乳腺癌患者、两名子宫内膜癌患者和一名肉瘤患者。对脱发和不适进行照片记录和患者评估。结果：在接受蒽环类药物治疗的患者中，观察到脱发完全得到预防，而在接受紫杉醇/多西他赛治疗的患者中，脱发很少甚至没有。蒽环类药物和紫杉烷类药物的组合会导致更多脱发，但六名患者中只有三人使用假发。头皮冷却一般都能很好地耐受； 74 名患者中只有两人因不适而停止使用冷帽。中位随访时间为 15 个月，未出现头皮转移。结论：数字化、受控、头皮冷却系统代表了一种有效且安全的装置，应在随机试验和使用其他化疗方案的研究中进行临床评估，以确定最佳温度和冷却持续时间以获得最大功效。
Goals: The aim of this study was to examine the efficacy and safety of a new digitized, controlled, scalp-cooling system to prevent chemotherapy-induced alopecia. Method: Seventy-four female cancer patients who received 13 varying chemotherapy regimens were included in a nonrandomized pilot study. The Digni 2-3 with Dignicap system consists of a refrigerator unit and a control unit integrated into a mobile cabinet and connected to a tight-fitting cooling cap. This system maintains a constant scalp temperature of +5degreesC for many hours. In this study, 60 patients were treated for ovarian cancer with either taxane or epirubicin combination chemotherapy. Eight patients with Hodgkin's lymphoma, three with breast cancer, two with endometrial cancer, and one with sarcoma were also included. Photo documentation and patient assessment of hair loss and discomfort were performed. Results: In anthracycline-treated patients, total prevention of hair loss was observed, whereas hair loss in paclitaxel/docetaxel-treated patients was minimal to none. The combination of anthracycline and taxane resulted in more hair loss, but only three of six patients used a wig. Scalp cooling was generally very well tolerated; only two of 74 patients discontinued use of the cold cap due to discomfort. No scalp metastases occurred over a median follow-up period of 15 months. Conclusions: The digitized, controlled, scalp-cooling system represents an effective and safe device that should be clinically evaluated in a randomized trial and in studies using other chemotherapy regimens to determine optimal temperatures and durations of cooling for maximal efficacy.